STRYKER CORP
SYK · Healthcare · FY2025 filings · · not refreshed in 35 days · Narrow moat ·
On the watchlist
The five investor questions
2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $17.1B to $25.1B, increasing; diluted EPS 5.21 to 8.40, increasing.
Median gross margin 64.0% over 10y, very stable.
Median ROIC 10.3%, above the 12% hurdle in 20% of years.
Net debt/EBITDA 1.8x, interest coverage 8x.
Owner earnings changed +8.7%/yr over up to the ten most recent annual observations.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- $3.7B
- Unavailable — insufficient owner-earnings data
- Unavailable — insufficient growth-model data
- $330.25
- No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 4% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
20 years of fundamentals
The business, in plain English
STRYKER CORP booked $25.1B of revenue in FY2025 in the Healthcare sector and kept 64.0% of it as gross profit — a high-margin business by that measure. After every other cost, 12.9% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $6.0B (FY2007) to $25.1B (FY2025) — about 8.3% a year compounded over 18 years.
It earned 10.3% on invested capital in the latest filed year, FY2025. Across the full 19-year measurable filed record, median ROIC was 11.7%. Over the v3 recent window (10 measurable filed years), median ROIC was 10.3%. The Returns on Capital filter above scores it 30/100.
The balance sheet carried $15.9B of total debt in FY2025 against $4.1B of owner earnings — roughly 3.9 years of owner earnings to retire it all. Balance-Sheet Safety scores it 45/100.
Put together: Pricing Power is the strongest of the five filters (100/100) and Returns on Capital the weakest (30/100), which is how SYK lands at 68/100 — a Narrow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in SYK’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for SYK.
Track record
How STRYKER CORP’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored SYK on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the 4 years SYK rated Wide-moat (2011, 2012, 2013 and 2016), the median forward total return that followed — measured only after each year’s filings were public — was:
- 1 year 31% vs the S&P 500’s 17% (price basis) · median over 4 years
- 3 years 76% vs the S&P 500’s 41% (price basis) · median over 4 years
- 5 years 145% vs the S&P 500’s 81% (price basis) · median over 4 years
These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.
Healthcare context
#64 of 710 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #62HALO HALOZYME THERAPEUTICS, INC.68.2 out of 100, Narrow moatNarrow moat
- #63ABT ABBOTT LABORATORIES67.7 out of 100, Narrow moatNarrow moat
- #65SI Shoulder Innovations, Inc.67.3 out of 100, Narrow moatNarrow moat
- #66CARL CARLSMED, INC.67.2 out of 100, Narrow moatNarrow moat
Compare SYK with its nearest peers →All Healthcare companies on the Index →
Common questions about SYK
- Does STRYKER CORP have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores STRYKER CORP (SYK) 67.7 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 95, pricing power 100, returns on capital 30, balance-sheet safety 45, capital allocation 69.
- How has SYK's Moat Score changed over time?
- The record logs 16 readings since Jul 17, 2026; the latest reads 67.7 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.